Fate Therapeutics (FATE)
(Real Time Quote from BATS)
$3.31 USD
-0.06 (-1.78%)
Updated Aug 12, 2024 12:26 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
FATE 3.31 -0.06(-1.78%)
Will FATE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FATE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FATE
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
ChromaDex (CDXC) Reports Break-Even Earnings for Q2
FATE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Other News for FATE
Commit To Purchase Fate Therapeutics At $2.50, Earn 22.1% Annualized Using Options
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
Fate Therapeutics appoints Neely Mozaffarian to board of directors
Fate Therapeutics Appoints AI Expert to Enhance Board